The application prospects of pemetinib/pemetinib in China

Pemigatinib/Pemigatinib, an innovative drug targeting patients with cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, has recently been approved by the National Medical Products Administration and has officially entered the domestic market, providing a new treatment option for patients with advanced cholangiocarcinoma. The approval was based on results from two pivotal clinical studies.

Among them,FIGHT-202 study demonstrated the significant efficacy of pemetinib in patients with locally advanced or metastatic cholangiocarcinoma. In this phase 2, multicenter study, pemetinib not only demonstrated an impressive overall response rate (ORR), but also demonstrated a long duration of response (DOR). What is even more exciting is that in a bridging study conducted in China, pemetinib also showed excellent efficacy, and the drug was well tolerated by Chinese patients.

Cholangiocarcinoma, a malignant tumor originating from bile duct epithelial cells, has an increasing incidence rate in my country in recent years. For many patients, the chance of surgical resection is lost due to late detection of the condition. Traditional chemotherapy and radiotherapy regimens often have limited efficacy and severe side effects. Therefore, the approval of pemetinib undoubtedly brings new hope to these patients.

Pemetinib’s unique mechanism of action enables it to precisely inhibit the growth and spread of tumor cells withFGFR mutations. This strong selective inhibition not only improves the efficacy, but also reduces damage to normal cells, thereby reducing the occurrence of side effects. This advantage makes pemetinib likely to become one of the first-line treatment options for patients with cholangiocarcinoma in the future.